Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.62 |
| ▸ | CIT | O14578 | 7/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
| ▸ | CHUK | O15111 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009247 | 0.94 | CIT (0.62) | JAK1CITSLC22A12IKBKBCHUK | |
| SCHEMBL30009873 | 0.85 | JAK1 (0.60) | JAK1CITIKBKBCHUKBRD4 | |
| SCHEMBL30008979 | 0.85 | CIT (0.59) | JAK1CITIKBKBCHUKBRD4 | |
| SCHEMBL30010048 | 0.80 | IKBKB (0.73) | CITIKBKBCHUK | |
| SCHEMBL30009619 | 0.80 | CIT (0.56) | JAK1CITIKBKBCHUKJAK2 | |
| SCHEMBL30009497 | 0.79 | JAK1 (0.61) | JAK1CITIKBKBCHUKBRD4 | |
| SCHEMBL30008778 | 0.78 | CIT (0.61) | JAK1CITIKBKBCHUK | |
| SCHEMBL30008811 | 0.78 | CIT (0.60) | JAK1CITIKBKBCHUK | |
| SCHEMBL20917997 | 0.77 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30008938 | 0.77 | CIT (0.60) | JAK1CITIKBKBCHUKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885CIT 417/4885SLC22A12 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.